These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25017515)

  • 1. Aurora kinase A is a possible target of OSU‑03012 to destabilize MYC family proteins.
    Silva A; Wang J; Lomahan S; Tran TA; Grenlin L; Suganami A; Tamura Y; Ikegaki N
    Oncol Rep; 2014 Sep; 32(3):901-5. PubMed ID: 25017515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
    Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
    Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
    Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
    Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
    Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
    Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
    J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
    PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.
    Otto T; Horn S; Brockmann M; Eilers U; Schüttrumpf L; Popov N; Kenney AM; Schulte JH; Beijersbergen R; Christiansen H; Berwanger B; Eilers M
    Cancer Cell; 2009 Jan; 15(1):67-78. PubMed ID: 19111882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
    Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
    Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
    Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
    Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
    Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
    Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
    Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
    Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
    Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
    J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.
    Boratyn E; Nowak I; Durbas M; Horwacik I; Sawicka A; Rokita H
    J Cell Biochem; 2017 Jul; 118(7):1741-1755. PubMed ID: 27935099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.
    Kang J; Rychahou PG; Ishola TA; Mourot JM; Evers BM; Chung DH
    Oncogene; 2008 Jun; 27(28):3999-4007. PubMed ID: 18278068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma.
    Maris JM
    Cancer Cell; 2009 Jan; 15(1):5-6. PubMed ID: 19111875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.